Uptake of Papanicolaou testing by HPV vaccination status

Gabriel Chodick1,2, Amy E. Leader3, Sharon Larson2,3

1) MaccabiTech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel
2) Main Line Health Center for Population Health Research at Lankenau Institute for Medical Research, Wynnewood, PA
3) Jefferson University College of Population Health, Thomas Jefferson University, Philadelphia, PA

Disclosures: The authors have no disclosures for this study.

Abstract

Background: Although the annual incidence of cervical cancer in Israel is relatively low (5.4 per 100,000), the Ministry of Health recommends human papillomavirus (HPV) vaccination among females and males at 8th grade as part of the national childhood immunization program. It is unclear whether young Israeli women who initiated HPV vaccination are more likely than unvaccinated women to report having a Papanicolaou (Pap) test later in life.

Objectives: To evaluate the impact of the HPV vaccine on cervical cancer screening program and to examine if uptake of Pap testing differed across subgroups of age and income by vaccination status.

Methods: Design and settings: This retrospective cohort analysis was carried out at Maccabi Healthcare Services (MHS), a 2.3-million-enrollee, integrated-care provider in Israel. From all women immunized with at least one dose of HPV vaccine from its introduction in Israel in June 2007 to Dec. 2018, we excluded those who had a Pap test prior to vaccination, as well as women who were no longer members of MHS on Dec. 2018. Over 20,000 eligible vaccinated women were individually matched with non-vaccinated MHS members on a one-to-one basis by exact birth year, socioeconomic level, and district of residence. Exposure: HPV immunization was collected from the women’s electronic medical records (EMR), as well as information on demographic factors (date of birth, district of residence, enumeration area), body mass index, and if ever smoked cigarettes. Socioeconomic status was categorized according to the poverty index of the members’ enumeration area. Main outcome: Data on the uptake of Pap smears were extracted from EMR in the laboratory, and the number of Pap smears for each woman during the study period was counted. Statistical analysis: We started follow-up at the date of purchase of first vaccination dose and then followed them forward until Pap test or Dec. 2018, whichever occurred first. We used Cox proportional hazards regression, with days of follow-up as the time scale.

Results: Proportion of women having Pap test was significantly higher among HPV vaccinated women (7.7% vs. 5.1%; P<0.001). Adherence of Pap smear tests among vaccinated women was significantly higher compared to non-vaccinated women across all relevant age groups.

Conclusions: We found no indication for lower adherence with Pap tests among women who were immunized with HPV vaccine than in the past.

Background

- Cervical cancer is caused by oncogenic types of HPV.
- In Israel, HPV vaccinations are recommended for females and males at 8th grade.
- The HPV vaccine is ineffective against non-vaccine oncogenic type or in patients with prior infections. As such, cervical cancer screening is still essential for cancer prevention.
- Guidelines in Israel recommend Pap testing at 3-year intervals from age 25, regardless of HPV vaccination status.
- Two HPV vaccines are available in Israel (Cervarix®, Glaxo Smith Kline; and Gardasil®®, Merck that was introduced in Israel June 2007). Vaccination was opportunistic, as it was not covered by the National Health Insurance Act. At first it was indicated for females aged 9 to 26 years; since 2012 it was expanded to females aged 9 to 45 years.
- Recent literature has indicated that women who initiated HPV vaccination were more likely than unvaccinated women to report having a Pap test in the previous 3 years.

Objectives

- We aimed to evaluate the impact of the HPV vaccine on a cervical cancer screening program in Israel and to examine if uptake of Pap testing differed across subgroups of age and income by vaccination status.

Methods

- Using the database of MHS, which covers 25% of the total population in Israel, we identified a total of 47,690 women immunized with at least one dose of HPV vaccine from its introduction in Israel in June 2007 to December 2018.
- Excluded from the study were women who had a Pap test prior to vaccination (n=24,642), as well as women who were no longer members of MHS on December 2018 (n=2,121). All eligible vaccinated women (n=20,904) were individually matched with non-vaccinated MHS members on a one-to-one basis by exact birth year, socioeconomic level, and district of residence.
- Data on the uptake of Pap smears were extracted from MHS central laboratory, and the number of Pap smears for each woman during the study period was counted.
- We collected information on demographic factors, body mass index, poverty index, and smoking.
- Retrospective follow-up was from date of purchase of first HPV vaccination dose through date of first Pap test or December 2018, whichever occurred first.

Table 1: Characteristics of study population by HPV vaccination status

<table>
<thead>
<tr>
<th>Vaccination Status</th>
<th>Age at index date</th>
<th>BMI</th>
<th>Smoking</th>
<th>SES, Median (IQR)</th>
<th>Pap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not vaccinated</td>
<td>19.68 (3.88)</td>
<td>23.56 (4.98)</td>
<td>1.01</td>
<td>2467 (2121)</td>
<td>242</td>
</tr>
<tr>
<td>Vaccinated</td>
<td>19.23 (4.58)</td>
<td>23.08 (4.41)</td>
<td>0.95</td>
<td>2018 (2018)</td>
<td>238</td>
</tr>
</tbody>
</table>

Results

- Characteristics of study population are given in Table 1.
- Cumulative rates of Pap screening tests among women vaccinated with HPV by the end of follow-up was higher (26.8%) as compared to non-vaccinated females (22.4%).
- Cumulative rates of Pap screening tests by HPV vaccination status among women aged 15-24 years and 25-34 years at HPV vaccination are given in Figures 1 and 2, respectively.
- In a multivariable model, HPV vaccination was associated with a significantly (P=0.001) higher likelihood (adjusted HR= 1.34; 1.29-1.41) for performing HPV screening test as compared to non-vaccinated females.

Table 2: Cox Proportional hazards model for Pap smear test

<table>
<thead>
<tr>
<th>Smoking</th>
<th>HR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>1</td>
<td>(Ref.)</td>
</tr>
<tr>
<td>Current</td>
<td>.87</td>
<td>.74-.99</td>
</tr>
<tr>
<td>Past</td>
<td>.93</td>
<td>.76-1.11</td>
</tr>
</tbody>
</table>

Results

- Cumulative rates of Pap screening tests, by HPV vaccination status (age: 15-24y)
- Cumulative rates of Pap screening tests, by HPV vaccination status (age: 25-34y)

Conclusions

We found no indication for lower adherence with Pap tests among women who were immunized with HPV vaccine than in the past. These results are supported by reports of the U.S. National Health Interview Survey that indicate young women who had not initiated HPV vaccination have lower uptake of Pap test compared to women who had initiated vaccination.

Contact details: hodik_g@mac.org.il • www.maccabitech.com • Presented at the 35TH INTERNATIONAL CONGRESS ON PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT (ICPE)